Can Auvelity (dextromethorphan‑bupropion) increase the risk of mania, especially in patients with bipolar disorder?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 23, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Can Auvelity Increase Mania Risk?

Yes, Auvelity (dextromethorphan-bupropion) can precipitate manic, mixed, or hypomanic episodes, particularly in patients with bipolar disorder or risk factors for bipolar disorder, and is explicitly not approved for treating bipolar depression. 1

FDA-Mandated Warning on Mania Risk

The FDA drug label for Auvelity clearly states that antidepressant treatment can precipitate a manic, mixed, or hypomanic episode, with the risk appearing increased in patients with bipolar disorder or who have risk factors for bipolar disorder 1. This is a critical safety consideration that must guide prescribing decisions.

Required Pre-Treatment Screening

Before initiating Auvelity, you must:

  • Screen all patients for a personal history of bipolar disorder
  • Screen for risk factors including family history of bipolar disorder, suicide, or depression 1
  • Recognize that Auvelity is not approved for use in treating bipolar depression 1

The Bupropion Component and Mania Risk

While bupropion has historically been considered to have a "lower" risk of inducing mania compared to other antidepressants, recent evidence challenges this assumption:

Evidence Against the "Lower Risk" Claim

A 2016 meta-analysis found that the rate of phase shifting (switching to mania/hypomania) with bupropion was not significantly different from other antidepressants (P = 0.952) 2. This directly contradicts the traditional belief that bupropion carries less mania risk and should prompt heightened vigilance when prescribing to any patient with bipolar risk factors.

Case Reports Document Real-World Risk

Two case reports from 2019 documented manic shifts in bipolar patients when bupropion was added as an adjunct to mood stabilizer treatment 3:

  • A 43-year-old female on lithium and quetiapine developed manic symptoms after bupropion addition
  • A 26-year-old male on lithium and valproate developed psychotic mania requiring hospitalization after bupropion addition
  • Both cases showed rapid improvement after bupropion discontinuation 3

Clinical Context: Antidepressants and Bipolar Disorder

The broader evidence on antidepressants in bipolar disorder provides important context:

General Antidepressant Risk in Bipolar Disorder

Guidelines emphasize that antidepressants may destabilize mood or incite a manic episode in bipolar patients 4. Critically, antidepressants should only be used as adjuncts when the patient is also taking at least one mood stabilizer 4.

A retrospective review found that 58% of youths with bipolar disorder experienced emergence of manic symptoms after exposure to mood-elevating agents, most often antidepressants 4.

Important Distinction

A manic episode precipitated by an antidepressant is characterized as substance-induced per DSM criteria 4. However, this does not diminish the clinical significance—the patient still experiences a manic episode with all its associated morbidity and potential for harm.

Practical Clinical Algorithm

When Auvelity is Contraindicated:

  • Any patient with diagnosed bipolar I or II disorder (Auvelity is not approved for bipolar depression) 1
  • Patients with history of antidepressant-induced mania/hypomania
  • Patients with strong family history of bipolar disorder without adequate mood stabilizer coverage

If Considering Auvelity in At-Risk Patients:

  1. Do not prescribe if any bipolar disorder diagnosis exists
  2. If risk factors present but no diagnosis:
    • Complete thorough screening for bipolar spectrum symptoms
    • Assess family psychiatric history in detail
    • Consider alternative treatments with lower activation risk
  3. Never use Auvelity as monotherapy in patients with any bipolar risk factors

Monitoring Requirements:

  • Educate patients and families about early warning signs of mania: decreased need for sleep, increased energy, racing thoughts, impulsivity, increased goal-directed activity
  • Schedule early follow-up (within 1-2 weeks of initiation)
  • Discontinue immediately if any manic or hypomanic symptoms emerge 1

Common Pitfall to Avoid

Do not rely on the historical notion that bupropion has a "lower" mania risk. The most recent meta-analysis shows no significant difference in phase-shifting rates compared to other antidepressants 2. This outdated belief may lead to false reassurance and inadequate monitoring.

Additional Safety Considerations

Beyond mania risk, Auvelity carries other neuropsychiatric warnings:

  • Psychosis, delusions, hallucinations, and confusion have been reported with bupropion, particularly in patients with bipolar disorder 1
  • Dextromethorphan overdose can cause toxic psychosis 1
  • The combination requires monitoring for neuropsychiatric reactions 1

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.